GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (STU:AWK) » Definitions » Operating Cash Flow per Share

Avadel Pharmaceuticals (STU:AWK) Operating Cash Flow per Share : €-1.37 (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Avadel Pharmaceuticals Operating Cash Flow per Share?

Avadel Pharmaceuticals's operating cash flow per share for the three months ended in Mar. 2024 was €-0.30. Avadel Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.37.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -21.80% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Avadel Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:

STU:AWK' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -65.7   Med: 11.2   Max: 36.8
Current: -21.8

During the past 13 years, Avadel Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 36.80% per year. The lowest was -65.70% per year. And the median was 11.20% per year.

STU:AWK's 3-Year OCF Growth Rate is ranked worse than
82.6% of 799 companies
in the Drug Manufacturers industry
Industry Median: 6.9 vs STU:AWK: -21.80

Avadel Pharmaceuticals Operating Cash Flow per Share Historical Data

The historical data trend for Avadel Pharmaceuticals's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals Operating Cash Flow per Share Chart

Avadel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.92 -0.73 -1.17 -1.10 -1.47

Avadel Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.44 -0.38 -0.40 -0.29 -0.30

Competitive Comparison of Avadel Pharmaceuticals's Operating Cash Flow per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Avadel Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avadel Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avadel Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Avadel Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.



Avadel Pharmaceuticals Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Avadel Pharmaceuticals's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )=Cash Flow from Operations (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=-117.845/80.174
=-1.47

Avadel Pharmaceuticals's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )=Cash Flow from Operations (Q: Mar. 2024 )/Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
=-27.328/91.693
=-0.30

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avadel Pharmaceuticals Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Avadel Pharmaceuticals (STU:AWK) Business Description

Traded in Other Exchanges
Address
10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.